Evidence map›Paper›PMID 39224128›Full record

ArticleIn silico pharmacology2024

Exploring the therapeutic potential of prolinamides as multi-targeted agents for Alzheimer's disease treatment: molecular docking and molecular dynamic simulation studies.

Samuel O Olalekan, Vincent A Obakachi, Abosede A Badeji, Oyesolape B Akinsipo Oyelaja, Oluwole Familoni, Olayinka T Asekun, Segun D Oladipo, Adejoke D Osinubi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In silico pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Samuel O OlalekanDepartment of Physiology, Olabisi Onabanjo University, Sagamu Campus, Sagamu, Ogun State Nigeria.
Vincent A ObakachiDepartment of Chemical Sciences, University of Johannesburg, Doornfontein Campus, P.O. Box 17011, Johannesburg, 2028 South Africa.
Abosede A BadejiDepartment of Chemical Sciences, Tai Solarin University of Education, Ijagun, P.M.B. 2118, Ijebu Ode, Ogun State Nigeria.
Oyesolape B Akinsipo OyelajaDepartment of Chemical Sciences, Tai Solarin University of Education, Ijagun, P.M.B. 2118, Ijebu Ode, Ogun State Nigeria.
Oluwole FamiloniDrug Design Research Group, Department of Chemistry, University of Lagos, Akoka-Yaba, Lagos, 101245 Nigeria.
Olayinka T AsekunDrug Design Research Group, Department of Chemistry, University of Lagos, Akoka-Yaba, Lagos, 101245 Nigeria.
Segun D OladipoDepartment of Chemistry and Polymer Science, Stellenbosch University, Private Bag X1, Matieland, 7602 South Africa.
Adejoke D OsinubiDepartment of Chemical Sciences, Tai Solarin University of Education, Ijagun, P.M.B. 2118, Ijebu Ode, Ogun State Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) presents a significant global health challenge, with its prevalence expected to rise sharply in the coming years. Despite extensive research, effective treatments addressing the multifaceted pathophysiology of AD remain elusive. This study investigates the therapeutic potential of twenty-seven prolinamides (P1 - P27), with the focus on their interactions with key proteins implicated in AD pathogenesis. Four of the compounds, namely; 10-((4-nitrophenyl)prolyl)-10 H-phenothiazine (P14), 2-((4-nitrophenyl)prolyl)isoindoline (P19), 1-(4-formylphenyl)- Graphical Abstract: Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-024-00250-z.

Indexed as

Alzheimer’s diseaseMolecular dynamicsPharmacokineticsProlinamides

Identifiers

PMID39224128
PMCPMC11365881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.